S gene sequencing of SARS-CoV-2 clinical isolate - SRA

SRX14473554: S gene sequencing of SARS-CoV-2 clinical isolate
1 ILLUMINA (Illumina MiSeq) run: 36,833 spots, 10.5M bases, 5Mb downloads

Design: Viral RNA extraction on 1 mL of swab fluid by TRIzol-LS reagent, random primer cDNA synthesis by Invitrogen Superscript IV reverse transcriptase, S gene amplification using in-house nested PCR primers

Submitted by: Brigham and Women's Hospital

Study: SARS-CoV-2 Bamlanivimab resistance sequencing

PRJNA816433 • SRP364287 • All experiments • All runs

show Abstracthide Abstract

As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), non-hospitalized participants with symptomatic SARS-CoV-2 infection were given bamlanivimab (700mg or 7000mg) or placebo treatment. We performed targeted Spike (S) gene next-generation sequencing to detect bamlanivimab resistance mutations. Using this data, we can assess whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or therapeutic efficacy in the immune-competent population.

Sample: SARS-CoV-2 clinical targeted S gene sequencing

SAMN26675734 • SRS12274793 • All experiments • All runs

Organism: Severe acute respiratory syndrome coronavirus 2

Library:

Name: ACTIV2-1I839855168

Instrument: Illumina MiSeq

Strategy: AMPLICON

Source: VIRAL RNA

Selection: RT-PCR

Layout: SINGLE

Runs: 1 run, 36,833 spots, 10.5M bases, 5Mb

Run	# of Spots	# of Bases	Size	Published
SRR18337191	36,833	10.5M	5Mb	2022-03-18

ID:: 20654758

SRA

Sequence Read Archive

Result Filters

Send to:

Supplemental Content

Related information

Recent activity